---
title: "Zhongxing BioTech has repurchased a total of 4.5868% of its shares, costing approximately 140 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227343802.md"
description: "According to the Zhitong Finance APP, Zhongxing BioTech announced that as of January 31, 2025, the company has repurchased a total of 18.0372 million shares through a dedicated securities repurchase account via centralized bidding, accounting for 4.5868% of the company's current total share capital, with a highest transaction price of 8.00 yuan/share and a lowest transaction price of 7.19 yuan/share, for a total payment of 140 million yuan"
datetime: "2025-02-06T09:18:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227343802.md)
  - [en](https://longbridge.com/en/news/227343802.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227343802.md)
---

# Zhongxing BioTech has repurchased a total of 4.5868% of its shares, costing approximately 140 million yuan

According to the announcement from Zhongxing BioTech (002772.SZ), as of January 31, 2025, the company has repurchased a total of 18.0372 million shares through a dedicated securities repurchase account via centralized bidding, accounting for 4.5868% of the company's current total share capital, with a highest transaction price of 8.00 yuan/share and a lowest transaction price of 7.19 yuan/share, for a total payment of 140 million yuan

### Related Stocks

- [002772.CN](https://longbridge.com/en/quote/002772.CN.md)
- [00023.HK](https://longbridge.com/en/quote/00023.HK.md)

## Related News & Research

- [LEAD Launch Leaves Accountable Care Technology Buyers Little Time for a Wrong Decision, Q3 Study](https://longbridge.com/en/news/296106866.md)
- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [TGN: Net profit fell 51% year-over-year, but market cap reached a record high amid major investments](https://longbridge.com/en/news/296490198.md)
- [Fleury launches BRL 1.83 billion two-tranche unsecured debenture offering](https://longbridge.com/en/news/296407363.md)
- [Masoval to present Q2 2026 results in investor briefing](https://longbridge.com/en/news/296509895.md)